← Back to results
Federal

Finn Sawyer Access to Cancer Testing Act

Source: Congress.gov  ·  1,626 words in original text
This bill requires Medicare, Medicaid and the Children's Health Insurance Program (CHIP) to cover cancer diagnostic and laboratory tests. These tests include genetic analysis methods used to identify cancer mutations (genetic changes in cells). The bill also directs the Secretary of Health and Human Services to run an education program about genetic testing for doctors and the public.
Medicare beneficiaries (people age 65 and older or with certain disabilities), Medicaid recipients (low-income individuals and families), CHIP beneficiaries (targeted low-income children and pregnant women), physicians, and the general public.
• Medicare must cover cancer diagnostic and laboratory tests starting 6 months after the bill becomes law, paying 80 percent of the cost or 100 percent if the provider accepts the Medicare-approved amount (Sec. 2(a)(1)) • Cancer diagnostic and laboratory tests are defined as microarray analysis, DNA sequencing, RNA sequencing, whole-exome sequencing and other next-generation sequencing (a method of reading genetic information) provided by a clinical laboratory, along with explanation and interpretation of these tests (Sec. 2(a)(1)) • These tests may only be covered once at cancer diagnosis, once at cancer recurrence, and as needed for treatment planning or monitoring cancer response (Sec. 2(a)(1)) • Medicaid must cover cancer diagnostic and laboratory tests starting January 1, 2025 (Sec. 2(b)(5)(A)) • CHIP must cover cancer diagnostic and laboratory tests for low-income children and pregnant women starting January 1, 2025 (Sec. 2(c)) • The Secretary of Health and Human Services, working with the National Human Genome Research Institute, must create an education program for doctors and the public about what genetic testing is, how it works and the role of genetic counselors (Sec. 3(a))
Medicare will begin covering genetic tests used to diagnose and monitor cancer, with beneficiaries responsible for 20 percent of the cost. Medicaid programs and CHIP programs across all states will be required to cover these same genetic tests. Doctors will receive education and training on using molecular diagnostics (testing that identifies genetic mutations) when cancer is first diagnosed and when it recurs.
Cancer diagnostic and laboratory tests: microarray analysis, DNA sequencing, RNA sequencing, whole-exome sequencing and other next-generation sequencing furnished by a clinical laboratory, plus explanation and interpretation of these tests, provided to someone diagnosed with cancer.
Medicare coverage begins 6 months after the bill becomes law (Sec. 2(a)(1)). Medicaid and CHIP coverage begin January 1, 2025 (Sec. 2(b)(5)(A) and Sec. 2(c)).
Important: This plain English summary was generated by AI and is provided for informational purposes only. It is not legal advice. Always consult the official bill text on Congress.gov or a qualified attorney for legal matters.